| Severe acute respiratory syndrome coronavirus 2− specific antibody responses in coronavirus disease patients NMA Okba, MA Müller, W Li, C Wang, CH GeurtsvanKessel, VM Corman, ... Emerging infectious diseases 26 (7), 1478, 2020 | 1616 | 2020 |
| Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans BB Oude Munnink, RS Sikkema, DF Nieuwenhuijse, RJ Molenaar, ... Science 371 (6525), 172-177, 2021 | 1040 | 2021 |
| Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) JJA van Kampen, DAMC van de Vijver, PLA Fraaij, BL Haagmans, ... Nature communications 12 (1), 267, 2021 | 670 | 2021 |
| Clearance of influenza virus from the lung depends on migratory langerin+CD11b− but not plasmacytoid dendritic cells CH GeurtsvanKessel, MAM Willart, LS van Rijt, F Muskens, M Kool, ... The Journal of experimental medicine 205 (7), 1621-1634, 2008 | 575 | 2008 |
| SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients D Geers, MC Shamier, S Bogers, G den Hartog, L Gommers, ... Science immunology 6 (59), eabj1750, 2021 | 515 | 2021 |
| Tertiary lymphoid organs in infection and autoimmunity K Neyt, F Perros, CH GeurtsvanKessel, H Hammad, BN Lambrecht Trends in immunology 33 (6), 297-305, 2012 | 376 | 2012 |
| Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus–infected mice CH GeurtsvanKessel, MAM Willart, IM Bergen, LS van Rijt, F Muskens, ... Journal of Experimental Medicine 206 (11), 2339-2349, 2009 | 374 | 2009 |
| Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients CH GeurtsvanKessel, D Geers, KS Schmitz, AZ Mykytyn, MM Lamers, ... Science immunology 7 (69), eabo2202, 2022 | 369 | 2022 |
| An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment CH GeurtsvanKessel, NMA Okba, Z Igloi, S Bogers, CWE Embregts, ... Nature communications 11 (1), 3436, 2020 | 368 | 2020 |
| Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands BB Oude Munnink, DF Nieuwenhuijse, M Stein, Á O’Toole, M Haverkate, ... Nature medicine 26 (9), 1405-1410, 2020 | 327 | 2020 |
| Convalescent plasma for COVID-19. A randomized clinical trial A Gharbharan, CCE Jordans, C Geurtsvankessel, JG den Hollander, ... MEDRxiv, 2020.07. 01.20139857, 2020 | 279 | 2020 |
| Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants JJA van Kampen, DAMC van de Vijver, PLA Fraaij, BL Haagmans, ... MedRxiv, 2020.06. 08.20125310, 2020 | 249 | 2020 |
| Division of labor between dendritic cell subsets of the lung CH GeurtsvanKessel, BN Lambrecht Mucosal immunology 1 (6), 442-450, 2008 | 246 | 2008 |
| SARS-CoV-2 specific antibody responses in COVID-19 patients NMA Okba, MA Müller, W Li, C Wang, CH GeurtsvanKessel, VM Corman, ... MedRxiv, 2020.03. 18.20038059, 2020 | 235 | 2020 |
| Diagnostic testing for SARS-CoV-2: interim guidance World Health Organization World Health Organization, 2020 | 199 | 2020 |
| Miscarriage associated with Zika virus infection AA van der Eijk, PJ van Genderen, RM Verdijk, CB Reusken, R Mögling, ... New England Journal of Medicine 375 (10), 1002-1004, 2016 | 173 | 2016 |
| Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection A Gharbharan, CCE Jordans, C GeurtsvanKessel, JG den Hollander, ... Nature communications 12 (1), 3189, 2021 | 170 | 2021 |
| COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety A Fendler, EGE de Vries, CH GeurtsvanKessel, JB Haanen, B Wörmann, ... Nature Reviews Clinical Oncology 19 (6), 385-401, 2022 | 160 | 2022 |
| mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial SF Oosting, AAM van der Veldt, CH GeurtsvanKessel, RSN Fehrmann, ... The Lancet Oncology 22 (12), 1681-1691, 2021 | 146 | 2021 |
| The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a … JSF Sanders, FJ Bemelman, AL Messchendorp, CC Baan, D van Baarle, ... Transplantation 106 (4), 821-834, 2022 | 140 | 2022 |
